top of page

Research study focused on the safety and efficacy of Lutetium-177-PSMA-I&T in Metastatic Castration-Resistant Prostate Cancer

Thank you for your interest in Curium's ECLIPSE research study! Participating in this study presents an investigational therapy option for patients that may help advance innovation in metastatic castration-resistant prostate cancer treatment.


Metastatic castration-resistant prostate cancer treatment
Lutetium Lu-177 for metastatic prostate cancer treatment



The purpose of this research study is to compare the safety and efficacy of Lutetium Lu-177-PSMA-I&T versus standard-of-care hormone therapy in patients with metastatic castration-resistant prostate cancer.

Lu-177-PSMA-I&T for metastatic prostate cancer treatment

Why Target PSMA?


Prostate-specific membrane antigen (PSMA) is found in large numbers at the surface of prostate tumor cells. The study drug, Lutetium Lu-177-PSMA-I&T, attaches to the PSMA and is taken inside the tumor cell. The radiation inside the tumor cell causes DNA damage which results in the tumor cell death.

Randomization for metastatic prostate cancer clinical trial

All Patients Receive Treatment


Patients will be randomized using a 2:1 ratio of study medication to standard-of-care hormone therapy for metastatic castration-resistant prostate cancer. Participants receiving standard-of-care treatment may have the option to receive the study drug, Lutetium Lu-177-PSMA-I&T, if disease progression is detected.

Study Overview - What can you expect?

If you are eligible for the Curium ECLIPSE research study, you will be randomly assigned to receive either Lutetium Lu-177-PSMA-I&T or standard-of-care hormone therapy. During the research study, you will visit the study site to receive treatment, blood tests, and imaging exams and you will be monitored for progression of your disease. Once the treatment portion of the study has ended, the study team will continue to follow up with you for up to five years.


This study of Lutetium Lu-177-PSMA-I&T, a radiopharmaceutical, is being performed for research purposes only. The safety and effectiveness of Lutetium Lu-177-PSMA-I&T have not been established by the FDA. It cannot be promised that patients will receive any medical benefits from participating in this study. Patients will be compensated for their time. However, your participation in this study could help lead to the approval of a new treatment for metastatic castration-resistant prostate cancer.

Do I Qualify?

How do I know if I am eligible?

To find out if you may be eligible for the research study, please fill out the pre-screening questionnaire by clicking “Begin eligibility check”. If the questionnaire identifies you as a potential participant, you will be contacted by a member of the study team to gather more information and determine the closest study site to you. As part of the screening process, you may be asked to provide your medical history and travel to the study site for lab assessments and imaging exams.

Curium Eclipse mCRPC logo

This site is produced and managed by THREAD Research on behalf of Curium. Patients should consult their physicians when considering enrollment in any clinical trial, including ECLIPSE. CT0005 1022

If you are a healthcare professional, please visit the HCP Website

bottom of page